Teleflex Incorporated (TFX) Business Profile

What it does

Teleflex Incorporated designs, makes and supplies medical technology used by hospitals and healthcare providers. Founded in 1943 and headquartered in Wayne, Pennsylvania, it is led by President and Chief Executive Officer Jason Weidman. Most of its business consists of single-use devices for diagnostic and treatment procedures, including care for critically ill patients and surgery.

Its vascular products include catheters used to deliver intravenous therapies, measure blood pressure or collect blood samples. It also sells devices that allow clinicians to deliver fluids and medicines through bone when access to a vein is difficult, as well as products used to help control bleeding.

The interventional business supplies devices used to diagnose and treat coronary and peripheral vascular disease. Its products include catheters, devices to close vascular access sites, stents and balloons. The surgical business sells instruments and devices such as ligating clips, closure systems and a powered bariatric stapler.

Teleflex sells through its own sales force and distributors. In 2026, it began managing and reporting its operations as three global business units: vascular, interventional and surgical.

The company has also been changing its portfolio. It completed the sale of its original equipment manufacturer, or OEM, business in 2026. Its planned sale of the Acute Care and Interventional Urology businesses remained subject to regulatory review as of November 2026.

How it makes money

Teleflex earns revenue by selling medical devices to hospitals, healthcare providers and distributors. Substantially all of its net revenue comes from single-use devices. Hospitals and providers generally place orders for delivery within days or weeks, rather than relying on a backlog that indicates future revenue.

For FY2025, Vascular Access revenue was $917.7 million, Interventional revenue was $647.8 million and Surgical revenue was $418.2 million. The FY2025 figures are presented on a continuing-operations basis, excluding the businesses designated for divestiture.

Vascular products support activities ranging from intravenous access and emergency infusions to bleeding control. Interventional products support procedures involving blood vessels and the heart; the acquisition of BIOTRONIK’s Vascular Intervention business added products including drug-coated balloons, stents and balloon catheters. Surgical products include both single-use and reusable instruments for a range of procedures.

Teleflex sells directly through its own sales force and through independent representatives and distributors. It may convert distributor relationships to direct sales, either by acquiring a distributor or ending the relationship. These conversions are intended to improve product pricing and give it more direct access to end users.

The business also receives revenue from manufacturing and transition services associated with the completed OEM sale. Teleflex expects service arrangements associated with the pending Acute Care and Interventional Urology sale to be more extensive, because the buyer requires more support.

Customers and how it sells

Teleflex’s customers include hospitals, healthcare providers and distributors. Its products are used by clinicians including interventional cardiologists, interventional radiologists, vascular surgeons and other surgical teams. Some emergency-access and bleeding-control products are also intended for use outside hospitals, including by first responders.

The company reaches customers through its own sales force, independent representatives and distributor networks. Its products are used in numerous markets and procedures, and it is not dependent on any one end-market or procedure. Most of its customer relationships outside the United States are with government entities because of the prevalence of government-sponsored healthcare systems.

In FY2025, the United States accounted for 59.3% of revenue, Europe for 24.3% and Asia Pacific for 10.9%. Teleflex previously reported geographic segments for the Americas, Europe, the Middle East and Africa, and Asia. In 2026, it shifted to managing and reporting through global vascular, interventional and surgical business units.

For EasyPlaz, its freeze-dried plasma product, Teleflex’s initial priority is the U.S. government and military market. Commercial delivery to that market still requires procurement solicitation, contract negotiation and execution.

Suppliers and costs

Teleflex’s major manufacturing operations are in the Czech Republic, Malaysia, Mexico and the United States. It buys manufacturing and sterilization materials from suppliers across several countries. It is not dependent on a single supplier for a substantial amount of the materials, components or sterilization services used across its overall operations.

Most materials, components and sterilization services are available from multiple sources, and Teleflex seeks alternatives where practical. Establishing alternative sources can nevertheless be delayed by regulatory requirements governing manufacturing and sterilization. Commodity prices and freight costs can affect the cost of producing and supplying some products.

Tariffs increased import costs in 2025, including costs associated with its European operations and certain products manufactured in Mexico. Its responses include supply-chain changes and pricing actions. In the third quarter of 2026, adjusted gross margin included a refund related to tariff payments made earlier that year.

The company is also restructuring its operations. It expects its multi-year plan to generate annual pre-tax cost savings upon completion in mid-2028.

Competitive position

Teleflex competes in a medical-device industry that includes start-ups and companies larger and more established than itself. No individual competitor is named. The market is characterized by product research and development and technological advances, and Teleflex must continue to develop and acquire products and technologies to remain competitive.

Teleflex competes on clinical performance and features, reliability, product performance, customer and sales support, and cost-effectiveness. It owns and licenses patents and trademarks, but does not consider any single patent or trademark essential to its business apart from the Teleflex name and Arrow brand.

Our reading: The Arrow brand and Teleflex’s sales relationships provide some commercial differentiation, but the evidence does not establish a strong barrier against other device makers. Our reading: Regulatory clearance requires expertise and time, but most of the company’s existing and pipeline devices are in categories that generally follow a less demanding pathway than the approval process for higher-risk devices.

Teleflex says EasyPlaz is the first and only FDA-licensed freeze-dried plasma and that it is stored at room temperature. The company expects the U.S. government and military to account for most of its current manufacturing capacity, while increasing supply will require a multi-year effort. Our reading: Its licensed position gives it an early product advantage, though limited capacity and unfinished procurement steps constrain the near-term opportunity.

Growth opportunities

Teleflex seeks to grow through new products and extensions, broader applications for existing technology, expansion into new geographic markets and selected acquisitions, licenses and partnerships. It also pursues direct sales conversions and operating efficiencies.

The 2025 acquisition of BIOTRONIK’s Vascular Intervention business added coronary and peripheral devices to its interventional portfolio. Integration has taken longer than planned, although Teleflex made progress during the third quarter of 2026 in moving customers to its ordering platform, transitioning distributors and filling sales territories.

The company is increasing research and development spending and directing more of it toward new products. Its Freesolve resorbable magnesium scaffold received FDA breakthrough device designation for coronary intervention. Enrollment in the Biomag-2 trial is complete, with a data readout expected in late 2027, and the U.S. pivotal Biomag-3 trial is underway.

Teleflex sizes the long-term potential U.S. market for EasyPlaz at at least $200.0 million. It expects revenue from the product to be immaterial in 2026, to contribute in 2027 and then to ramp modestly over the first several years. The company must build the market, and substantially increasing production will take a multi-year effort.

For 2026 continuing operations, Teleflex expects pro forma adjusted constant currency revenue growth.

Structural risks

• Regulation and product quality: Teleflex’s devices and manufacturing facilities are subject to regulatory requirements and inspections. Noncompliance can lead to recalls, production restrictions, penalties or delays in approvals. The company must also obtain new European certifications for devices previously authorized under earlier rules.
• Integration: The acquired Vascular Intervention business has experienced customer, distributor and sales-force transitions. Integration has taken longer than planned, and Teleflex is still developing processes for consignment sales.
• Divestiture execution: The Acute Care and Interventional Urology sale remains subject to regulatory review. The review concerns product overlap with the buyer, and closing could extend into 2027. Costs remaining after divestitures also affect continuing operations.
• Supply and trade costs: Finding alternative materials or sterilization services can be delayed by regulatory requirements. Tariffs, freight costs and commodity-price volatility can increase the cost of supplying products.
• Debt and cash demands: Teleflex’s indebtedness can require cash to be devoted to debt payments rather than investment and can limit borrowing or operating flexibility. The company used borrowings to finance the Vascular Intervention acquisition.
• Product demand: Teleflex recognized an impairment charge in 2025 for its Titan SGS asset group after lower-than-expected sales growth and a downward revision to forecasts. It also anticipated reduced demand for bariatric procedures associated with growing adoption of GLP-1 products.

Bottom line

Our reading

Teleflex is primarily a supplier of single-use devices for hospital procedures, with vascular access, interventional and surgical products sold through direct and distributor channels (item1; item7). Its portfolio changes and acquired interventional business create opportunities to reshape the business, but integration work and the pending divestiture remain important execution demands (item7; call_prepared). EasyPlaz and Freesolve add development opportunities, while procurement, manufacturing capacity and clinical or regulatory progress will determine how those opportunities develop (call_prepared).